FREE Case Review (866) 588-0600

Abilify Gambling Lawsuits May Be Consolidated into MDL

Multidistrict litigation (MDL) status being considered for federal lawsuits alleging uncontrollable compulsive behaviors from Bristol-Myers’ antipsychotic medication Abilify.

More than 2 dozen lawsuits alleging that the antipsychotic medication Abilify (generic: aripiprazole) caused gambling addiction and other compulsive behaviors could soon be formed into a multidistrict litigation (MDL).

Free Confidential Lawsuit Evaluation: If you or a loved one experienced compulsive behaviors after taking Abilify, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer and our lawyers can help.

What’s the Problem?

June 30, 2016 – According to a Motion for Transfer order filed last Friday with the U.S. Judicial Panel on Multidistrict Litigation (JPML), plaintiffs and Abilify’s manufacturers, Bristol-Myers Squibb (BMS) and Otsuka Pharmaceutical, agree that the formation of an MDL would benefit the litigation. The parties also agree that the U.S. District Court, Northern District of Florida, would be the best venue for the proposed MDL, according to Reuters.

There are currently at least 26 Abilify lawsuits pending in federal courts across the U.S., as well as 13 cases in New Jersey state court that have already been consolidated for pretrial coordination. The Motion for Transfer requests that the JPML expedite the matter and schedule oral arguments for its next hearing session, which is set for July 28 in Seattle.

Abilify is a second generation antipsychotic (SGA) used to treat schizophrenia, bipolar disorder and other serious psychiatric conditions in adults and children. The drug works by rebalancing dopamine and serotonin to improve thinking, mood and behavior.

On May 3, 2016, the FDA issued a Drug Safety Communication indicating that the labeling of all aripiprazole-containing medications (Abilify, Abilify Maintena, Aristada and generics) would be changed to include new warnings regarding compulsive behaviors such as gambling, sexual behavior, shopping and eating. The warning was prompted by FDA’s review of at least 184 case reports which suggested a potential link between use of aripiprazole and impulse control problems. All 184 cases occurred between November 2002 and January 2016, with the reports noting that uncontrollable urges stopped once the drug was discontinued or the dosage reduced, according to the agency.

All of the complaints filed over Abilify allege that BMS and Otsuka failed to adequately warn of the drug’s ability to cause compulsive behavior problems. An MDL would allow all pending federal cases, as well as those filed in the future, to undergo coordinated pretrial proceedings, including discovery and motions practice. This process promotes judicial efficiency, streamlines the litigation process, and serves the best interest of all parties involved. The proposed consolidation is In Re: Abilify Compulsive Behavior Products Liability Litigation – MDL No. 2734.

Do I Have an Abilify Lawsuit?

The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Abilify lawsuits. We are handling individual litigation nationwide and currently accepting new compulsive gambling cases in all 50 states.

Free Confidential Case Evaluation: Again, if you or a loved one experienced financial loss, family problems or legal consequences as a result of compulsive gambling while taking Abilify, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.

Free Confidential Case Evaluation

Verified 100% Secure SiteTo contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 588-0600.
Awards & recognition